首页> 美国卫生研究院文献>Pharmaceutical Biology >Effects of astaxanthin on blood coagulation fibrinolysis and platelet aggregation in hyperlipidemic rats
【2h】

Effects of astaxanthin on blood coagulation fibrinolysis and platelet aggregation in hyperlipidemic rats

机译:虾青素对高脂血症大鼠凝血纤溶和血小板聚集的影响

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

>Context: Astaxanthin (ASTX) is a xanthophyll carotenoid that reduces hemostasis in hyperlipidemic organisms. Its antihemostatic mechanisms remain unclear.>Objective: The effects of ASTX on coagulation, the fibrinolytic system and platelet aggregation were investigated in hyperlipidemic rats.>Materials and methods: Different doses of ASTX (5, 10 and 30 mg/kg/day, p.o.) were administered for four weeks to high-fat diet-induced hyperlipidemic rats. Serum lipid and lipoprotein levels were measured with an automatic biochemical analyzer. The prothrombin time (PT), activated partial thromboplastin time (APTT) and maximum platelet aggregation rate (MAR) were determined by a coagulation analyzer. The activities of the tissue-type plasminogen activator (t-PA), type-1 plasminogen activator inhibitor (PAI-1) and endothelial nitric oxide synthase (eNOS), as well as the levels of thromboxane B(2) [TXB(2)], 6-keto prostaglandin F(1α) [6-keto-PGF(1α)] and platelet granule membrane protein (GMP-140), were measured with enzyme-linked immunosorbent assay kits. Gene and protein expression levels were analyzed by reverse transcriptase polymerase chain reaction and Western blot, respectively.>Results: ASTX (30 mg/kg) treatment in hyperlipidemic rats reduced serum TG (0.58 ± 0.14 versus 1.12 ± 0.24 mmol/L), serum TC (1.77 ± 0.22 versus 2.24 ± 0.21 mmol/L), serum LDL-C (1.13 ± 0.32 versus 2.04 ± 0.48 mmol/L), serum MDA (69%), plasma MAR (55%), serum TXB2/6-keto-PGF1α (34%) and serum GMP-140 levels (25%), plasma PAI-1 activity (48%) and downregulated the mRNA (33%) and protein (23%) expression of aorta eNOS, the mRNA (79%) and protein (72%) expression levels of aorta PAI-1. However, ASTX (30 mg/kg/d) treatment increased serum SOD activity (2.1 fold), serum GPx activity (1.8 fold), plasma PT (1.3 fold), plasma APTT (1.7 fold), serum NO (1.4-fold), serum 6-keto-PGF1α (1.3 fold).>Conclusions: ASTX reduced blood coagulation and platelet aggregation and promoted fibrinolytic activity in hyperlipidemic rats. These activities were closely correlated with ASTX, maintaining the balance of t-PA/PAI-1, NO/ROS and TXA2/PGI2 in vivo.
机译:>上下文:虾青素(ASTX)是一种叶黄素类胡萝卜素,可减少高脂血症生物体的止血作用。 >目的:研究了ASTX对高脂血症大鼠凝血,纤溶系统和血小板聚集的影响。>材料和方法:不同剂量的ASTX( 5、10和30μmg/ kg /天,口服)给予高脂饮食诱导的高脂血症大鼠4周。用自动生化分析仪测量血清脂质和脂蛋白水平。用凝血分析仪测定凝血酶原时间(PT),活化的部分凝血活酶时间(APTT)和最大血小板聚集率(MAR)。组织型纤溶酶原激活物(t-PA),-1型纤溶酶原激活物抑制剂(PAI-1)和内皮型一氧化氮合酶(eNOS)的活性,以及​​血栓烷B(2)[TXB(2 )],6-酮基前列腺素F(1α)[6-酮基-PGF(1α)]和血小板颗粒膜蛋白(GMP-140)用酶联免疫吸附测定试剂盒测量。 >结果:高脂血症大鼠的ASTX(30μmg/ kg)处理降低了血清TG(0.58±0.14 vs 1.12±0.24)。结果: mmol / L),血清TC(1.77±0.22 vs 2.24±0.21mmol / L),血清LDL-C(1.13±0.32 vs 2.04±0.48 mmol / L),MDA(69%),血浆MAR(55%) ,血清TXB2 / 6-酮-PGF1α(34%)和血清GMP-140水平(25%),血浆PAI-1活性(48%)并下调主动脉的mRNA(33%)和蛋白质(23%)表达eNOS,主动脉PAI-1的mRNA(79%)和蛋白质(72%)表达水平。然而,ASTX(30μmg/ kg / d)处理可增加血清SOD活性(2.1倍),血清GPx活性(1.8倍),血浆PT(1.3倍),血浆APTT(1.7倍),血清NO(1.4倍) ,血清6-keto-PGF1α(1.3倍)。>结论: ASTX降低高脂血症大鼠的凝血和血小板凝集,并促进其纤溶活性。这些活性与ASTX密切相关,在体内维持t-PA / PAI-1,NO / ROS和TXA2 / PGI2的平衡。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号